Related Experiment Videos
Evidence for a pre-restriction point Cdk3 activity
Susan M Keezer1, David M Gilbert
1Department of Biochemistry and Molecular Biology, S.U.N.Y. Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA.
Abstract:
We have examined the activity of cyclin-dependent kinase 3 (cdk3) during G1-phase of the cell cycle in Chinese Hamster Ovary (CHO) fibroblasts. Histone H1 kinase activity associated with anti-cdk3 immunoprecipitates peaked during a brief window of time, 2-3 h prior to the restriction point. In vitro cdk3 activity was sensitive to roscovitine, a drug previously shown to inhibit cdks 1, 2, and 5, but not cdk4 or 6. Early G1-phase activation of cdk3 was downregulated by treatment of cells with MG132, an inhibitor of the proteasome, and by the protein synthesis inhibitor cycloheximide. These results provide evidence for a pre-restriction point cdk3 activity that requires both the synthesis of a regulatory subunit and degradation of an inhibitor.
Insights
Cyclin-dependent kinase 3 (cdk3) activity peaks before the restriction point in the cell cycle. This pre-restriction point activity requires new protein synthesis and the breakdown of an inhibitor.
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Background:
- Cyclin-dependent kinases (cdks) regulate cell cycle progression.
- The precise role of cdk3 in the G1-phase remains incompletely understood.
- Identifying key regulators of cell cycle transitions is crucial for understanding cell proliferation.
Purpose of the Study:
- To investigate the activity and regulation of cyclin-dependent kinase 3 (cdk3) during the G1-phase of the cell cycle.
- To determine the temporal window of cdk3 activation relative to the restriction point.
- To elucidate the molecular mechanisms controlling cdk3 activity.
Main Methods:
- Immunoprecipitation of cdk3 from Chinese Hamster Ovary (CHO) fibroblasts.
- Assay of histone H1 kinase activity in anti-cdk3 immunoprecipitates.
- Treatment with roscovitine, MG132 (proteasome inhibitor), and cycloheximide (protein synthesis inhibitor).
Main Results:
- Histone H1 kinase activity associated with cdk3 peaked 2-3 hours before the G1 restriction point.
- In vitro cdk3 activity was inhibited by roscovitine, consistent with inhibition of cdks 1, 2, and 5.
- Early G1-phase cdk3 activation was reduced by MG132 and cycloheximide, indicating dependence on protein synthesis and degradation.
Conclusions:
- A distinct pre-restriction point cdk3 activity exists during early G1-phase.
- This activity is regulated by the synthesis of a regulatory subunit and the degradation of an inhibitory protein.
- cdk3 plays a critical, temporally regulated role in the G1-phase transition.